Matched external control analysis of event-free survival (EFS) in patients with high-risk neuroblastoma (HRNB) receiving eflornithine (DFMO) maintenance. Javier E. Oesterheld, Genevieve Bergendahl, Donald A. Berry, Elizabeth Lorenzi, Thomas Clinch, Jacqueline M. Kraveka, William Ferguson, Valerie I. Brown, Don Eslin, Derek Hanson, Virginia Lynn Harrod, Michael Isakoff, Deanna Mitchell, Randal Wada, Peter E. Zage, Giselle Linda Saulnier Sholler, ASCO Annual Meeting, Chicago IL, Poster Platform Presentation, June 2022
